Medicare Officially Limits Aduhelm Coverage to Clinical Patients

Over the past few months, Medicare officials have been overflowing with enthusiasm for how coverage of the controversial new Alzheimer’s drug Aduhelm will be handled. Advocacy groups for patients said the federal insurance program for people 65 and older should pay for a drug approved by the Food and Drug Administration. Many Alzheimer’s doctors and …

Medicare Recommends Covering Aduhelm for Clinical Patients Only

Medicare officials have decided that the federal health insurance program should only cover the controversial new Alzheimer’s drug, Aduhelm, for patients participating in approved clinical trials. The preliminary decision, after lengthy deliberation, was published Tuesday by the Center for Medicare and Medicaid Services, or CMS. Finalization of the decision later this year will significantly limit …

Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision

Federal officials are grappling with a decision that could go a long way in determining the future of the controversial new Alzheimer’s drug, Aduhelm, and whether a significant number of patients are using it. In January, Medicare, the federal health insurance program for people 65 and older, plans to issue a preliminary ruling on whether …

Biogen’s Aduhelm Sales Total $2 Million in the Second Quarter

Pharmaceutical manufacturer Biogen reported its on thursday Controversial Alzheimer’s drug aduhelm It brought in $2 million in its first few weeks, which is the first revenue for a treatment that is expected to generate billions of dollars in a few years and strain Medicare’s budget. The company did not disclose the number of patients who …

Cleveland Clinic Says It Won’t Give Patients Aduhelm

In a striking reflection of the concern over approval of the controversial new Alzheimer’s drug Aduhelm, the Cleveland Clinic said Wednesday evening that it will not be administering it to patients. The clinic, one of the nation’s largest and most respected medical centers, said in a statement that a panel of experts “reviewed all available …